Hayward, R.L.

Leonard, R C

Prescott, Robin J

English

Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with Working Formulation high or intermediate grade non-Hodgkin's lymphoma. Clinical, pathological and investigational data were recorded prospectively on a computer database allowing analysis for prognostic factors. We have derived prognostically important characteristics and have tested prospectively the validity of the prognostic index on a geographically distinct sub-set of patients from the Edinburgh/Borders clinics. Multivariate analysis showed the following factors to be important in declining order of power; advancing age, worsening performance status, CNS/liver involvement, abnormal white cell count, 'B' symptoms and advancing clinical stage. Patient individual scores allowed them to be aggregated into one of three distinct prognostic groupings separated by arbitrary cut-points into a Best Group (39%) where the median survival exceeds 5 years (53% alive at 5 years), an Intermediate Group (30%) with median survival of 21 months (21% alive at 5 years), and a Worst Group (31%) whose median survival is 7 months (8% alive at 5 years). Similar prognostic group separations occurred when analysis was confined to: patients younger than 70 years; patients treated with initial chemotherapy; patients treated with initial radiotherapy; patients within any of the major pathological sub-groups

Edinburgh Research Explorer

5 others

A generalised Kruskal-Wallis test for comparing Ksamplessubject tounequal patterns ofcensorship.

A multivariate analysis of factors affecting survival in patients with highgradenon-Hodgkin'slymphoma.

Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Advances in chemotherapy for large cell lymphoma.

Chemotherapy for diffuse aggressive lymphomas.

Clinical relevance of immunologic phenotype in diffuse large cell lymphoma.

Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

Combined modality therapy of advanced non-Hodgkin's lymphoma: ananalysisofremissiondurationandsurvival in95patients.

COPBLAM III: Infusional dcombination chemotherapy for diffuse large cell lymphoma.

Current status and perspectives in the treatment ofnon-Hodgkin's lymphomas.

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement.

E.&6others(1984). Treatment ofdiffuse poorly differentiated lymphocytic lymphoma. An analysis of prognostic variables.

Effectofageon therapeutic outcome in advanced diffuse histiocytic lymphoma: the South West Oncology Group experience.

Factors predicting long-term survival in diffuse mixed histiocytic or undifferentiated lymphoma.

Factors predicting survival in adults with stage I and II large cell lymphoma treated with primary radiation therapy.

Factorspredictingforresponseandsurvival in adults with advanced non-Hodgkin's lymphoma.

Identification ofmajor prognostic subgroups ofpatients with large cell lymphoma treated with m-BACOD or M-BACOD.

Interpretation ofclinical trials in diffuse large cell lymphoma.

LYMPHOMA PATHOLOGIC CLASSIFICATION PROJECT

MACOP-B chemotherapy for malignant lymphomas and related conditions:

Malignant lymphomas of follicular centre cell origin in man. III. Prognostic features.

Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas.

Potential forprolongeddiseasefree survival following combination chemotherapy of non-Hodgkin's Lymphoma.

Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

Predictive model for prognosis in advanced diffuse histiocytic lymphoma.

Prognostic factors for advanced diffuse histiocytic lymphomas following treatment with combination chemotherapy.

Prognostic factors in non-Hodgkin's lymphoma: the importance ofsymptomatic stage as an adjunct to the Kielhistopathological classification.

Recent trends in the treatment ofnon-Hodgkin's lymphomas.

Regression models andlife tables.

Southwest Oncology Group Clinical Trials for intermediate and high grade non-Hodgkin's lymphomas.

Southwest oncology group trials for intermediate and high grade non-Hodgkin's lymphomas.

The COP-BLAM Programs: evolving chemotherapy concepts in large cell lymphoma.

The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.

Theroleofchemotherapy indiffuseaggressive lymphoma.

Updated clinical experience with MACOP-B.

A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party

A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party

Abstract

Similar works

Full text

Available Versions

Edinburgh Research Explorer